# Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer

Source: https://onco.cc/trials/nct07448142/  
OnCo record `nct07448142` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of pucotenlimab in colorectal cancer, run by Sun Yat-sen University, now recruiting.

## Summary

Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer is a phase 2, randomised interventional study registered as NCT07448142 by Sun Yat-sen University, with a registry enrolment figure of 50 participants, started 2026-03-15 and due to reach its primary completion in 2027-09-01. Interventions recorded: Low-dose radiotherapy; Pucotenlimab; CAPEOX/XELOX. Conditions listed: Colorectal Cancer (CRC). Primary outcome: Complete Response Rate (CR). Colorectal eligibility wording from the registry: "* Histologically confirmed rectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07448142
- Phase: 2
- Setting: A Randomized, Two-Arm, Open-Label Phase II Trial of Low-Dose Radiotherapy Sensitization Combined With Pucotenlimab and CAPEOX as Neoadjuvant Therapy for pMMR/MSS Locally Advanced Rectal Adenocarcinoma
- Sponsor: Sun Yat-sen University
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT07448142: https://clinicaltrials.gov/study/NCT07448142

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- drugs: [Pucotenlimab](https://onco.cc/drugs/pucotenlimab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07448142.json